Novel small-molecule inhibitors, neutralizing antibodies, or anti-sense nucleotides disrupting COL4A1 and COL13A1 should be developed and tested in patients with bladder cancer refractive to conventional therapies. This evidence concerns the gene COL13A1 and urinary bladder cancer.